Exploring Current and Emerging Data Sets to Move Treatment of Higher-Risk MDS Forward: A Focus on Novel Targets and Treatment Approaches

Target Audience
This educational program is directed toward the ASCO audience, including hematologists and medical oncologists interested in the treatment of HR-MDS. Other allied healthcare professionals, including pathologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with MDS are also invited to participate.

Program Overview
This online, on-demand virtual symposium brings together renowned experts in myelodysplastic syndromes (MDS). In this educational program these experts review the latest data regarding risk stratification and emerging treatment approaches for managing patients with higher-risk MDS. Using a case-based format, the panel discusses clinical implications, shares their perspectives and best practices, and forecasts applications of key clinical challenges and questions regarding the clinical management of higher-risk MDS including risk stratification methods, novel biomarkers, progression to acute myeloid leukemia, assessing transplant eligibility, selecting subsequent-line therapy, emerging combination treatment approaches, and managing adverse events for patients with higher-risk MDS.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Explain the criteria for MDS diagnosis, and guidelines for risk stratification among these patients
Determine the impact of risk assessment on treatment selection in patients with higher-risk MDS
Assess the efficacy and safety profiles for current and emerging agents/combinations in patients with higher-risk MDS
Evaluate updated clinical evidence from landmark trials in the context of current treatment algorithms for patients with higher-risk MDS